MASH Market Report 2034: Statistics, Revenue, Patient Pool, EMA, PDMA, FDA Approvals, Clinical Trials, Medication, MOA, ROA and Companies by DelveInsight

MASH Companies are Boehringer Ingelheim, Hepagene, Eli Lilly and Company, Hepion Pharmaceuticals, Ionis Pharmaceuticals, Galectin Therapeutics, Novo Nordisk A/S, Merck & Co., Zealand Pharma, Hanmi Pharmaceutical, Inventiva Pharma, Cirius Therapeutics, HighTide Biopharma, Pfizer, Lipocine, Corcept Therapeutics, Poxel SA, Enyo Pharmaceuticals, Akero Therapeutics, Zydus Therapeutics, 89bio, Viking Therapeutics, Boston Pharmaceuticals, Gilead Sciences, CytoDyn, Sagimet Biosciences, and others.
(Albany, USA) DelveInsight's Metabolic Dysfunction-Associated Steatohepatitis Market Insights report includes a comprehensive understanding of current treatment practices, MASH emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].
The MASH market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted MASH market size from 2020 to 2034, segmented by seven major markets. The Report also covers current MASH treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the MASH market.
Key Takeaways from the Metabolic Dysfunction-Associated Steatohepatitis Market Report
The total MASH market size in the 7MM was approximately USD 2,114 million in 2023 and is projected to increase during the forecast period (2024–2034).
In 2023, there were an estimated 42 million prevalent cases of MASH in the 7MM. Out of these, a total of ~15 million cases were diagnosed, and this number is projected to increase by the end of 2034 in the 7MM.
Leading MASH companies such as Inventiva Pharma, Novo Nordisk A/S, Cirius Therapeutics, Akero Therapeutics, 89bio, Boehringer Ingelheim, Zealand Pharma, Galectin Therapeutics, Lipocine, Viking Therapeutics, Eli Lilly and Company, Boston Pharmaceuticals, Pfizer, HighTide Biopharma, CytoDyn, Merck & Co., Hanmi Pharmaceutical, Hepagene (Shanghai), Hepion Pharmaceuticals, Enyo Pharmaceuticals, Gilead Sciences, Poxel SA, Zydus Therapeutics, Sagimet Biosciences, Ionis Pharmaceuticals, Corcept Therapeutics, and others are developing novel MASH drugs that can be available in the MASH market in the coming years.
The promising MASH therapies in the pipeline include Lanifibranor (IVA337), Semaglutide, Azemiglitazone (MSDC-0602K), Efruxifermin (EFX), BIO89-100 (Pegozafermin), Survodutide (BI 456906), GR-MD-02 (Belapectin), LPCN1144, VK2809, Tirzepatide, BOS-580, Ervogastat (PF-06865571) + Clesacostat (PF-05221304), HTD1801, Leronlimab (PRO 140), Efinopegdutide, HPG1860, Rencofilstat (CRV431), EYP001 (Vonafexor), Semaglutide/Cilofexor/Firsocostat, PXL065, Saroglitazar Magnesium, Denifanstat (TVB-2640), ION224, Miricorilant (CORT118335), and others.
In March 2024, Madrigal Pharmaceuticals' groundbreaking product, REZDIFFRA (resmetirom), a once-daily, oral THR-ß agonist, received accelerated endorsement from the US FDA based on results from the Phase III MAESTRO-NASH trial. This approval marks a significant stride in the medical landscape, as REZDIFFRA becomes the inaugural and sole FDA-sanctioned therapy for adults afflicted with non-cirrhotic MASH, accompanied by moderate to advanced liver scarring (fibrosis) corresponding to stages F2–F3 fibrosis.
Discover which therapies are expected to grab the major MASH market share @ Metabolic Dysfunction-Associated Steatohepatitis Market Report
Metabolic Dysfunction-Associated Steatohepatitis Overview
Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease that stems from metabolic dysfunction, often linked to obesity, diabetes, and other conditions of metabolic syndrome. MASH is characterized by the accumulation of fat in liver cells, accompanied by inflammation and liver cell injury, which can progress to fibrosis, cirrhosis, or even liver cancer.
The primary drivers of MASH include insulin resistance, obesity, type 2 diabetes, and dyslipidemia. Genetic predisposition and a sedentary lifestyle also play significant roles. Environmental factors, such as a poor diet high in sugars and fats, exacerbate the condition.
MASH is often asymptomatic in its early stages. When MASH symptoms occur, they can include fatigue, vague abdominal discomfort, or pain in the upper right quadrant. In advanced stages, signs of liver dysfunction such as jaundice, swelling of the abdomen or legs, and confusion may arise.
MASH Diagnosis involves a combination of clinical history, physical examination, and diagnostic tests. Blood tests measuring liver enzymes (ALT, AST) often indicate liver inflammation. Imaging techniques like ultrasound, MRI, or FibroScan can identify liver fat and fibrosis. In some cases, a liver biopsy is required to confirm the diagnosis and assess disease severity.
Metabolic Dysfunction-Associated Steatohepatitis Epidemiology Segmentation
The MASH epidemiology section provides insights into the historical and current MASH patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.
The MASH market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Prevalent Cases of MASH
Diagnosed Prevalent Cases of MASH
Gender-specific Diagnosed Prevalent Cases of MASH
Severity-specific Diagnosed Prevalent Cases of MASH
MASH Treatment Market
The approval of REZDIFFRA (resmetirom) in March 2024 represents a pivotal achievement in medical innovation, transforming the treatment landscape for MASH disease. This groundbreaking therapy addresses the root causes of MASH, offering renewed hope to patients grappling with this challenging condition. Clinical trials have shown impressive results, with REZDIFFRA effectively reducing symptoms like inflammation and fibrosis, enhancing liver function, and improving patients' quality of life. By providing healthcare professionals with a robust treatment option, this approval addresses a critical unmet need and has the potential to significantly alleviate the complications linked to advanced liver disease.
The prevalence of MASLD is strongly linked to type 2 diabetes mellitus and obesity, particularly in individuals with a higher body mass index. However, MASLD occurrence is reduced in T2DM patients receiving treatments such as sodium-glucose cotransporter-2 (SGLT2) inhibitors, GLP-1 receptor agonists, and insulin. Vitamin E, with its antioxidant properties, is regarded as a first-line pharmacological option for managing MASH, especially when dietary and lifestyle interventions are insufficient.
Metabolic Dysfunction-Associated Steatohepatitis Pipeline Therapies and Key Companies
Lanifibranor (IVA337): Inventiva Pharma
Semaglutide: Novo Nordisk A/S
Azemiglitazone (MSDC-0602K): Cirius Therapeutics
Efruxifermin (EFX): Akero Therapeutics
BIO89-100 (Pegozafermin): 89bio
Survodutide (BI 456906): Boehringer Ingelheim/Zealand Pharma
GR-MD-02 (Belapectin): Galectin Therapeutics
LPCN1144: Lipocine
VK2809: Viking Therapeutics
Tirzepatide: Eli Lilly and Company
BOS-580: Boston Pharmaceuticals
Ervogastat (PF-06865571) + Clesacostat (PF-05221304): Pfizer
HTD1801: HighTide Biopharma
Leronlimab (PRO 140): CytoDyn
Efinopegdutide: Merck & Co./Hanmi Pharmaceutical
HPG1860: Hepagene (Shanghai)
Rencofilstat (CRV431): Hepion Pharmaceuticals
EYP001 (Vonafexor): Enyo Pharmaceuticals
Semaglutide/ Cilofexor/ Firsocostat: Gilead Sciences
PXL065: Poxel SA
Saroglitazar Magnesium: Zydus Therapeutics
Denifanstat (TVB-2640): Sagimet Biosciences
ION224: Ionis Pharmaceuticals
Miricorilant (CORT118335): Corcept Therapeutics
Discover more about MASH drugs in development @ Metabolic Dysfunction-Associated Steatohepatitis Clinical Trials and Advancements
MASH Market Dynamics
The MASH market dynamics are expected to change in the coming years. Growing research activities and multiple clinical trials for MASH, driven by the rapid surge in its prevalence due to rising obesity and type 2 diabetes rates, highlight an active drug development pipeline and an expanding market size. The large pool of patients and lucrative growth opportunities present attractive prospects for key players, further supported by ongoing preclinical studies aimed at advancing imaging techniques for MASH diagnosis, potentially eliminating the need for invasive biopsy-based histopathological confirmation.
Furthermore, potential therapies are being investigated for the treatment of MASH, and it is safe to predict that the treatment space will significantly impact the MASH market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the MASH market in the 7MM.
However, several factors may impede the growth of the MASH market. Lack of awareness and negligence in the early stages of MASH by physicians often lead to disease progression, culminating in irreversible damage where liver transplantation becomes the only viable option. Diagnosing advanced MASH typically requires procedures like liver biopsy, which are costly, invasive, and risky. Regulatory challenges also pose hurdles, as the FDA mandates achieving one MASH endpoint for approval, while the EMA's draft guidance requires efficacy in both endpoints, potentially delaying first-mover approvals in major European markets. Additionally, access to expensive MASH treatments may be limited in certain regions, further hindering patient adoption.
Moreover, MASH treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, MASH market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact MASH market growth.
Download the report to understand which factors are driving MASH drugs and therapies in pipeline @ Metabolic Dysfunction-Associated Steatohepatitis Treatment Market
Scope of the Metabolic Dysfunction-Associated Steatohepatitis Market Report
Study Period: 2020–2034
Coverage: 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].
Metabolic Dysfunction-Associated Steatohepatitis CAGR: 17.9 %
Metabolic Dysfunction-Associated Steatohepatitis Market Size in 2023: USD 2.1 Billion
Key Metabolic Dysfunction-Associated Steatohepatitis Companies: Hepion Pharmaceuticals (NASDAQ: HEPG), Ionis Pharmaceuticals (NASDAQ: IONS), Galectin Therapeutics (NASDAQ: GALT), Novo Nordisk A/S (NYSE: NVO), Cirius Therapeutics (Private), HighTide Biopharma (TSX-V: HBT), Boehringer Ingelheim (Private), Hepagene (Private), Eli Lilly and Company (NYSE: LLY), Pfizer (NYSE: PFE), Lipocine (NASDAQ: LPCN), Corcept Therapeutics (NASDAQ: CORT), Poxel SA (EPA: POXEL), Enyo Pharmaceuticals (Private), Akero Therapeutics (NASDAQ: AKRO), Zydus Therapeutics (NSE: ZYDUSLIFE), 89bio (NASDAQ: ETNB), Viking Therapeutics (NASDAQ: VKTX), Boston Pharmaceuticals (Private), Gilead Sciences (NASDAQ: GILD), Merck & Co. (NYSE: MRK), Zealand Pharma (CPH: ZEAL), Hanmi Pharmaceutical (KRX: 128940), Inventiva Pharma (EPA: IVA), CytoDyn (OTCQB: CYDY), Sagimet Biosciences (NASDAQ: SGMT).
Key Pipeline Metabolic Dysfunction-Associated Steatohepatitis Therapies: Lanifibranor (IVA337), Semaglutide, Azemiglitazone (MSDC-0602K), Efruxifermin (EFX), BIO89-100 (Pegozafermin), Survodutide (BI 456906), GR-MD-02 (Belapectin), LPCN1144, VK2809, Tirzepatide, BOS-580, Ervogastat (PF-06865571) + Clesacostat (PF-05221304), HTD1801, Leronlimab (PRO 140), Efinopegdutide, HPG1860, Rencofilstat (CRV431), EYP001 (Vonafexor), Semaglutide/Cilofexor/Firsocostat, PXL065, Saroglitazar Magnesium, Denifanstat (TVB-2640), ION224, Miricorilant (CORT118335), and others
Therapeutic Assessment: Metabolic Dysfunction-Associated Steatohepatitis current marketed and emerging therapies
Metabolic Dysfunction-Associated Steatohepatitis Market Dynamics: Key Market Forecast Assumptions of Emerging Metabolic Dysfunction-Associated Steatohepatitis Drugs and Market Outlook
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Download the report to understand which factors are driving MASH market trends @ Metabolic Dysfunction-Associated Steatohepatitis Market Trends
Table of Contents
1. Key Insights
2. Report Introduction
3. Country-wise MASH Market Overview at a Glance
4. MASH Market Overview by Therapeutic Class
5. Methodology of MASH Epidemiology and Market
6. Executive Summary
7. Key Events
8. Disease Background and Overview
9. MASH Epidemiology and Patient Population
10. MASH Patient Journey
11. Marketed MASH Drugs
12. Emerging MASH Drugs
13. MASH Market Analysis
14. Key Opinion Leaders' Views
15. SWOT Analysis
16. Unmet needs
17. Market Access and Reimbursement
18. Appendix
19. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/ats-conference-coverage

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

CBC

9 hours ago

• CBC

U.S. science funding uncertainty reshapes grad school choices for Canadians

Social Sharing After graduating with a bachelor degree in mathematics from the University of Waterloo, Kareem Alfarra had hopes of continuing his studies in the United States. The American schools he looked at were better funded and had more opportunities than those in Canada, he said, and he'd already connected with some professors he'd like to work with. Alfarra, 22, applied to nine American universities, hoping for options, but he ended up being waitlisted and rejected for all of them. Most of them told him informally that budget uncertainties in the U.S. were making it difficult for them to accept graduate students, he said. He says one school even told him that in any normal year, he would have been accepted. "I was on top of the wait list … and I would have loved to go," he told CBC. Rather than waiting to hear, Alfarra decided to accept an offer at the University of Toronto, citing the funding uncertainty and political instability of the U.S. "I was very angry with the situation knowing that perhaps a year earlier or a few years later I would've gotten in." While that's just one student's story, universities on both sides of the border say that uncertainty brought on by the Trump administration is reducing options and upending research opportunities for graduate students — including Canadians. 'Closing off career pathways' More than 10,000 Canadians went to graduate school in the U.S. last year, according to data from the Institute for International Education, with 40 per cent pursuing science and health degrees. But there are two key federal sources that U.S. universities rely on to fund their labs and take in graduate students — the National Science Foundation (NSF) and National Institutes of Health (NIH) — that have been frozen or cut by the Trump administration. It's been a back and forth battle, with cases before the courts, and it's unclear where things will land. But the uncertainty is enough for some universities to reduce their admissions, inevitably trickling down to Canadian applicants. WATCH | How Trump's freeze on health research funding might hurt Canadian science: Canadian scientists worry after Trump pauses federal health spending 5 months ago Duration 2:01 In a statement to the CBC, the American Association of Universities described the stakes. "Federal research funding cuts are actively closing off career pathways for all prospective doctoral students from across the world, including those from the United States and Canada," said Emily Miller, vice president for research and institutional policy at the association. "Universities make a significant financial commitment when they offer admission to an aspiring scientist or researcher — a commitment that is critical to student success and one they cannot meet without federal research support." A 'turbulent' landscape For 23 year old Canadian Jaeden Bardati, research funding was a big component in his decision to pursue his PhD in astrophysics at Caltech in Pasadena, Calif., two years ago. "Which is kind of ironic now," he said. on research and development in 2022; in the U.S., that figure was nearly 3.6 per cent in the same year. Bardati would ultimately like to be where the top researchers in his field are, which historically had been the U.S., he says, but that may change. Budget uncertainty makes some researchers worried whether they can maintain their labs or pay the students that work in them. Bardati says some of his classmates have been encouraged to graduate early or to fund themselves to be able to stay. "The landscape is very turbulent … the word that's been used around here is turbulent," said Bardati, which makes it difficult for students and researchers to plan for the future. "They're essentially trying to find a new home at the moment. And they're thinking, 'should I go to Europe or should I go to Canada?'" U.S. students applying north Katie Marshall, associate professor in comparative physiology at the University in British Columbia, is already starting to see the effects of this shift. She's received five applications from U.S. students to come work in her lab. "Usually, I wouldn't start seeing these kinds of applications until the fall," she said. "It's definitely unusual." Marshall also noted that the funding cuts in the U.S. are affecting research in Canada, because cross-border collaboration means Canadian researchers have gotten funding from U.S. agencies. "With less money, there's just fewer spots [for graduate students]." "When I look at who I'm going to accept, I'm looking at their research experience, " said Marshall. "If I've got a great American student, it's really hard for me to say no." While Canada can't fill the gap left by the US, it is a good time to invest in Canadian research to create more opportunities, said Marshall, noting that there has been some recent increases already.

National Post

14 hours ago

• National Post

Does rice contain arsenic? Yes, here's how you can reduce the risk

Arsenic in rice isn't a new concern, but a recent report published by Healthy Babies Bright Futures (HBBF) brought the issue back into the spotlight. The study found arsenic in all 145 rice samples bought at stores across the United States. More than a quarter surpassed 100 parts per billion (ppb) of inorganic arsenic, the Canadian and American federal limits for infant rice cereal. Article content Article content Article content Article content 'With all things to do with food safety, it comes down to reducing the risk of exposure,' says Lawrence Goodridge, a professor at the University of Guelph's Department of Food Science and director of the Canadian Research Institute for Food Safety, who wasn't involved in the HBBF report. 'People can reduce their risk by consuming less of those foods.' Article content Arsenic was 'the poison of choice in Victorian times,' says Keith Warriner, a professor at the University of Guelph's Department of Food Science, who wasn't involved in the HBBF report. It's also ubiquitous. 'The reality is, arsenic is everywhere. So it's not a case where you can avoid it.' Article content Warriner underscores that people shouldn't stop eating rice altogether because of arsenic. After all, it's a staple of many cuisines with cultural significance and health benefits. 'It's a concern to have, but it's not 'I'm going to give up rice' because there are things we can do to minimize.' Article content Article content Here are ways to reduce the risk, from the rice you buy and how you cook it to diversifying your diet with grains lower in heavy metals such as arsenic. Article content Article content The more toxic of its chemical forms, inorganic arsenic is considered a carcinogen and is naturally present in soil and groundwater. Article content Long-term exposure has been associated with an increased risk of health problems, including cancer, cardiovascular disease and skin lesions. When exposure happens in utero or during childhood, it 'may affect development and increase the risk of cancer in adulthood,' according to Health Canada. Article content Babies and young children are 'the real concern,' says Goodridge. The toxicity accumulates more easily because they're smaller and their body weight is lower. Article content 'Infant rice products can be a source of significant exposure,' he adds. 'It doesn't mean you can't give it to your kids, but limit it. It shouldn't be the primary grain cereal that they're fed. It shouldn't be the primary milk that they're given.'

CTV News

16 hours ago

• CTV News

Pricey TikTok skin care routines for kids raise alarms in new study

Children as young as seven are making TikTok videos about their meticulous and pricey skin care routines. Known as 'Sephora Kids,' they are the focus of a new study that raises alarms about the trend. 'We found that the skin care routines posted by creators aged 18 and under were complicated, costly, and time consuming,' lead author and dermatologist Dr. Molly Hales told 'The skin care routines offered few benefits to the young people that they were targeting, and they carried risks of irritation, skin allergy, and sun sensitivity.' Hales is a postdoctoral research fellow at Northwestern University's medical school in Chicago. For the study, Hales and another researcher created new TikTok accounts posing as 13-year-olds. They analyzed 100 skin care videos by content creators ages 7 to 18, and recorded the number and types of products that were used, as well as the total cost of each skin care regimen. On average, the content creators used six products per video. The average cost of the products used in each regimen was US$168 while the most expensive exceeded $500. The videos the researchers analyzed had an average of 1.1 million views. The 25 most-viewed videos featured products with an average of 11, and a maximum of 21, ingredients that could potentially lead to skin irritation, sun sensitivity or skin allergy. 'We found significant dermatologic risks associated with these regimens, including a very high risk of irritation,' Hales added in a news release from Northwestern University. 'That high risk of irritation came from both using multiple active ingredients at the same time, such as hydroxy acids, as well as applying the same active ingredient unknowingly over and over again when that active ingredient was found in three, four, five different products.' Only a quarter (26.2 per cent) of daytime skin regimens included sunscreen, which Hales says is an incredibly important product for young and old skin alike. 'It's really the only product that is recommended in this age group for those who don't have a known skin condition such as acne or eczema,' Hales told 'It's particularly important given that we found in our study that the most popular active ingredients in these youth skin care routines are alpha hydroxy acids, which are known to increase sun sensitivity.' In one video, a content creator applied 10 products to her face in six minutes – and quickly regretted it. 'You can see that she's turning bright red,' Hales said. 'She wraps up the video by saying, 'If anyone knows how to get it to stop burning, that would be greatly appreciated because it actually hurts a lot.'' Senior author and pharmacist Dr. Tara Lagu also noted potential harms that went beyond just product ingredients. 'We saw that there was preferential, encoded racial language in some cases that really emphasized lighter, brighter skin,'Lagu, an adjunct lecturer at Northwestern University, said in the news release. 'I think there also were real associations between use of these regimens and consumerism.' Lagu got the idea for the study after asking her 12-year-old niece what she wanted for Christmas and getting a list of $300 worth of skin care products. 'After digging around a bit, she realized that nobody had done a formal study of the skin care routines that were circulating among teens and pre-teens on social media,' Hales told 'She approached me about a potential collaboration, knowing that I'm both a dermatologist and a medical anthropologist with a background in digital and social media.' Published in the American Academy of Pediatrics, it is the first peer-reviewed study of its kind. The study's authors conclude that the videos offer little to no benefit for their young audience. They also note that it can hard for parents to track what their children are viewing on TikTok because of age-based algorithms. 'I would encourage parents to make sure that their kids understand that they don't need to be using tons of costly products in order to have healthy skin, or to take care of themselves and their skin,'Hales told 'These skin care videos can be fun and playful, and given their popularity, they likely aren't going away anytime soon. But it's troubling when this content sets an unrealistic standard of beauty and then promotes it in the name of 'health.'' Dr. Elena Hope, the head of pediatric dermatology at SickKids hospital in Toronto, was not involved in the study but echoed its recommendations. She said children should avoid using products with fragrances, essential oils and retinoids, urging parents to educate themselves about potentially harmful ingredients. 'Daily moisturizers that have been tested for tolerability and sunscreens are the only recommendations we have for children,' Hope said in an email to 'All other preparations are not needed and may be harmful.'